LQDA vs RLAY
Liquidia Corporation vs Relay Therapeutics, Inc. — AI-powered side-by-side comparison
LQDA
Liquidia Corporation
68
Buy
VS
RLAY
Relay Therapeutics, Inc.
65
Buy
| Metric | LQDA | RLAY |
|---|
| AI Score |
68
|
65
|
| Price |
$88.09
|
$20.00
|
| P/E Ratio |
368.26×
|
-12.73×
|
| ROE |
-154.0%
|
-48.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.8%
|
-566.6%
|
| Debt / Equity |
1.70×
|
0.03×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
55.0
|
66.0
|
| Beta |
0.572
|
1.704
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for LQDA versus RLAY.
LQDA leads by 3 points.
LQDA scores 68/100 (Buy) versus RLAY at 65/100 (Buy).
LQDA Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 46.8% shows genuine earnings power backing the valuation — Value
- Revenue growing 1936.7% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 362.9 is expensive by classic value standards — Value
- Price-to-book of 12.9x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
RLAY Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is roe of only -42.3% -- cheap may mean cheap for a reason. The committee is constructive but not yet at full conviction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- ROE of only -42.3% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical